Peter M. Hecht - Jan 1, 2024 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Role: Director, 10%+ Owner
Signature: /s/ Peter M. Hecht
Stock symbol: CYCN
Transactions as of: Jan 1, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/26/2024, 04:07 PM
Previous filing: Dec 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYCN	Common Stock	Award	$0	+15K	+4.14%	$0.00	377K	Jan 1, 2024	Direct	F1
holding	CYCN	Common Stock						24	Jan 1, 2024	The 2000 Trust for Alexis Mae Hecht	F2
holding	CYCN	Common Stock						24	Jan 1, 2024	The 2000 Trust for Malcolm Peter Hecht	F2
holding	CYCN	Common Stock						24	Jan 1, 2024	The 2000 Trust for Zoe Niovi Hecht	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted 15,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. These 15,000 shares are subject to vesting over a 47- month period, provided that the Reporting Person remains a consultant to the Cyclerion Therapeutics or a member of the board of directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.
F2	These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose.

Content

The Reporting Person was granted 15,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. These 15,000 shares are subject to vesting over a 47- month period, provided that the Reporting Person remains a consultant to the Cyclerion Therapeutics or a member of the board of directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose.